News and Media

On July 7, 2022, the Bulgarian Credit Rating Agency (BCRA) has awarded the company with the highest market capitalization on the Bulgarian Stock Exchange Tchaikapharma a long-term credit rating of “BBB-” and a short-term “A” on a national scale. With this, BCRA expresses its opinion that the company maintains a very good financial position with low levels of indebtedness, high creditworthiness, formed satisfactory liquidity, allowing it to timely service its obligations. According to the BCRA’s rating scale, the rating assigned corresponds to an ‘investment grade’ credit rating.

According to the agency’s analysis, the company is a well-established player in the local market with a long-standing (22 years) presence, a well-known name and reputation and an extensive commercial network.

“Politicians in power have one main task – to create a competitive investment and business environment and deal with the growth of the national economy. The self-esteem of any nation is a product of GDP per capita. Politicians should focus on this issue.” This is what Tihomir Kamenov, a specialist in public and private law, founder of the company group Commercial League, the only Bulgarian senior member of the World Economic Forum in Davos, told BNR.

Read more here.

Tchaikapharma has expanded its portfolio with another product, namely Fluidoro 10 mg film-coated tablets (with active ingredient prasugrel). It belongs to a group of drugs called platelet antiaggregants – it inhibits the accumulation of platelets and thus reduces the risk of blood clots.

Fluidoro, given concomitantly with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndrome (e.g., unstable angina, non-ST segment elevation myocardial infarction, or ST segment elevation myocardial infarction undergoing primary or delayed percutaneous coronary intervention (PCI).

The medicinal product is available on prescription.

ATC code: B01AC22

Tchaikapharma’s product portfolio was presented at the 6th congress of the Society of Cardiologists of Kosovo under the auspices of the European Society of Cardiology. Тhe company’s top products Tamaira, Co-Telsart, Amariton and Rosta were of particular interest as the preferred choice of the cardiologists in the country. This is one of the reasons why there has been a steady growth of Tchaikapharma’s sales in Kosovo in recent years.

The pandemic has caused problems in the forefront of predictability and access to medicines in the country. It was difficult to supply the basic (active) substances for pharmaceutical production, and a slight increase in the production of drugs.

In this context, even before the first global lockdown, the team of Tchaikapharma has prepared a stategy for action in the unprecedented situation, by defining three main challenges.

The full article is available here in Bulgarian.